(HealthDay News) — The U.S. Preventive Services Task Force (USPSTF) has concluded that the benefits and harms of low-dose aspirin for prevention of cardiovascular disease (CVD) and cancer vary by patient age. These findings form the basis of a draft recommendation statement published online September 14 by the USPSTF.

Researchers from the USPSTF reviewed the evidence relating to use of low-dose aspirin to prevent CVD and cancer. They then prepared recommendations that address different age groups.

The researchers found that for adults aged 50–59 years who have a ≥10% 10-year CVD risk and are not at increased risk for bleeding, low-dose aspirin should be taken to prevent CVD and colorectal cancer (Grade B recommendation). For individuals aged 60–69 years with a ≥10% 10-year CVD risk, the decision to use low-dose aspirin should be an individual one (Grade C recommendation). For adults <50 years and for those age ≥70, the current evidence was insufficient to weigh the balance of benefits and harms of aspirin use (Grade I statements). These findings form the basis of the draft recommendation statement, which will be available for comment until October 12.

“Taking aspirin is easy, but deciding whether or not to take aspirin for prevention is complex,” task force vice chair Kirsten Bibbins-Domingo, PhD, MD, said in a statement.

Draft Recommendation Statement
Draft Evidence Review 1
Draft Evidence Review 2
Draft Evidence Review 3